ArticleInternational archives of allergy and immunology2026
Omalizumab for Injection (Enyitan®) in Elderly Patients with Chronic Spontaneous Urticaria: Maintenance of Treatment Goals - A 6-Month Retrospective Follow-Up of Real-World Evidence.
Article in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic spontaneous urticaria (CSU) can be particularly burdensome for older adults. Real-world evidence regarding the use of omalizumab in this growing demographic remains limited. This study evaluated the effectiveness and safety of domestic omalizumab for injection (Enyitan®) in elderly patients with CSU under real-world conditions.
methodsIn this retrospective, single-center, observational cohort study, 71 CSU patients aged ≥65 years with moderate-to-severe disease activity were treated with omalizumab (Enyitan®, 300 mg every 4 weeks) between January and February 2025. Primary outcome was the proportion of patients achieving well-controlled disease (UAS7 ≤ 6) at week 24. Secondary outcomes included changes in UAS7, Itch Severity Score (ISS), Wheal Score (WS), Urticaria Control Test (UCT), and Dermatology Life Quality Index (DLQI). Safety was assessed via adverse events (AEs) and laboratory parameters.
resultsOf 62 patients completing the 24-week study, 88.7% achieved a UAS7 ≤ 6. ISS and WS scores similarly improved (p < 0.001). UCT scores increased from 5.2 ± 2.1 to 14.8 ± 3.2, and DLQI scores decreased from 15.6 ± 4.3 to 3.1 ± 2.8 (both p < 0.001). Treatment was well-tolerated; only mild, transient AEs were reported, predominantly injection-site reactions (9.7%) and headache (3.2%).
conclusionDomestic omalizumab (Enyitan®) demonstrated rapid, sustained effectiveness and a favorable safety profile in elderly patients with H1-antihistamine-resistant CSU, supporting its use as a first-line biologic therapy in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.